// App-Quantinova.ai

TPS6092 : ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

Researchers

Presenter

  • Ezra E.W. Cohen

Principal Investigators

  • Ranee Mehra

  • Amanda Psyrri

  • Julie E. Bauman

  • Richard Schaub

  • Li Zhou

  • Li Li

  • Vijayvel Jayaprakash

  • Joel Guigay

Medical Centers

  • University of California, San Diego, La Jolla, CA

  • Johns Hopkins Medicine, Baltimore, MD

  • Attikon Hospital, National Kapodistrian, University of Athens, Athens, Greece

  • University of Arizona College of Medicine Tuscon, Tuscon, AZ

  • Incyte Corporation, Wilmington, DE

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Centre Antoine-Lacassagne, Nice, France

Locations

  • United States

  • France

  • Greece

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Serpin B3

Drug/Treatment

  • Carboplatin

  • epacadostat

  • Erbitux

  • Cisplatin

  • Nivolumab

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03342352

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved